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Background: Cobicistat is an alternative pharmacoenhancer to ritonavir. In healthy volunteers, darunavir exposure
was comparable when darunavir 800 mg once daily was co-administered with cobicistat 150 mg once daily
(as single agents or a fixed-dose combination) vs. with ritonavir 100 mg once daily.
Methods: This 48-week, Phase IIIb, single-arm, US multicenter study (NCT01440569) evaluated safety, efficacy and
pharmacokinetics of darunavir/cobicistat 800/150 mg once daily (as single agents) plus two investigator-selected
nucleoside/tide reverse transcriptase inhibitors (N[t]RTIs) in HIV-1-infected adults. Patients had no darunavir
resistance-associated mutations (RAMs), plasma viral load (VL) ≥1000 HIV-1 RNA copies/ml, eGFR ≥80 ml/min and
genotypic sensitivity to the two N[t]RTIs. The primary endpoint was any treatment-emergent grade 3 or 4 adverse
events (AEs) through Week 24.
Results: The majority of the 313 intent-to-treat patients were treatment-naïve (295/313; 94%), male (89%), White
(60%) and received a tenofovir-based regimen (99%). Median baseline VL and CD4+ count overall were 4.8 log10
HIV-1 RNA copies/ml and 361 cells/mm3, respectively. Overall, 86% of patients (268/313) completed the study. The
majority of discontinuations were for AEs (15/313; 5%). The incidence of treatment-emergent grade 3 or 4 AEs
regardless of causality was 6% through Week 24 and 8% through Week 48. Most common AEs through Week 48
were diarrhea (27%) and nausea (23%), which were grade 1 or 2 in severity. Week 48 virologic response rates
(% with VL <50 HIV-1 RNA copies/ml; Snapshot analysis) were 81% overall and 83% in treatment-naïve patients;
median increases in CD4+ count at 48 weeks were 167 and 169 cells/mm3, respectively. Of 15/313 patients who
met the criteria for resistance analysis, one developed a darunavir RAM as a mixture with wild-type (I84I/V), without
phenotypic resistance to darunavir. The mean population pharmacokinetic-derived darunavir areas under the plasma
concentration–time curve were 102,000 overall and 100,620 ng•h/ml in treatment-naïve patients. No clinically relevant
relationships were seen between darunavir exposure and virologic response, AEs or laboratory parameters.
Conclusion: Darunavir/cobicistat 800/150 mg once daily was generally well tolerated through Week 48, with no new
safety concerns. Pharmacokinetics, virologic and immunologic responses for darunavir/cobicistat were similar to
previous data for darunavir/ritonavir 800/100 mg once daily.
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Treatment guidelines for HIV-1 infection [1-4] include
the recommendation of a ritonavir-boosted protease in-
hibitor (PI), such as darunavir/ritonavir, in combination
with other antiretrovirals. In two randomized, controlled
Phase III trials, darunavir/ritonavir 800/100 mg once
daily demonstrated antiviral efficacy with long-term tol-
erability in treatment-naïve (ARTEMIS; TMC114-C211)
[5-7] and treatment-experienced patients with no daru-
navir resistance-associated mutations (RAMs) (ODIN;
TMC114-C229) [8].
Low-dose ritonavir (100 mg once daily or twice daily)
is used as a pharmacokinetic enhancer [9]. Ritonavir is
a potent inhibitor of cytochrome P450 (CYP) 3A, and
thereby increases the oral bioavailability of most HIV-1
PIs, including darunavir [9,10]. Low-dose ritonavir is as-
sociated with gastrointestinal disorders, such as diarrhea
and nausea [9], hyperlipidaemia [11], and also clinically
significant drug–drug interactions [12].
Cobicistat (GS-9350) is also a potent inhibitor of
CYP3A and a pharmacoenhancer [13-16]. Cobicistat has
no antiviral activity, does not induce CYP isozymes, and is
more selective than ritonavir in terms of CYP3A inhib-
ition [13,14]. Cobicistat can be coformulated into fixed-
dose combinations [17], thereby reducing pill burden
and medication errors [18-22]. Cobicistat has been
evaluated as part of a single-tablet regimen with elvi-
tegravir, emtricitabine and tenofovir in clinical studies
of HIV-1-infected, antiretroviral treatment-naïve adults
[15,16,23-28]. Cobicistat 150 mg once daily for 144 weeks
was generally well tolerated. Small decreases in esti-
mated glomerular filtration rate calculated using the
Cockcroft-Gault method (eGFRCG) were observed with
cobicistat in these studies, which are attributable to in-
hibition of the tubular secretion of creatinine leading to
creatinine increases as early as Week 2 and stabilizing
by Week 24 through Week 144, without affecting renal
function (actual GFR, aGFR) as measured by iohexol
renal clearance [29].
A fixed-dose formulation of darunavir/cobicistat has
been developed. A Phase I study demonstrated compa-
rable darunavir pharmacokinetic parameters following
darunavir 800 mg once daily co-administered with cobi-
cistat 150 mg once daily, either as single agents [30] or
as two candidate fixed-dose combination formulations
[31] to those of darunavir/ritonavir 800/100 mg once daily.
Bioequivalence of darunavir administered as a fixed-dose
combination with cobicistat vs. single agents, was estab-
lished under fasted or fed conditions [32].
The aim of this Phase IIIb study was to evaluate the
safety, tolerability, efficacy and pharmacokinetics of daru-
navir in combination with cobicistat (as single agents) with
a background regimen of two, fully active, investigator-
selected nucleoside/tide reverse transcriptase inhibitors(N[t]RTIs) in HIV-infected treatment-naïve and -experienced
adults with no darunavir RAMs.
Results
Patient disposition and baseline characteristics
The first patient in the study began treatment on October
24 2011, and the last patient in the study had their Week
48 visit on January 31 2013.
Of the 397 patients screened, 313 were enrolled and in-
cluded in the intent-to-treat (ITT) population (Figure 1).
One patient was not treated. Most of the 83 screening fail-
ures were due to screening eGFRCG <80 ml/min or scree-
ning viral load (VL) <1000 HIV-1 RNA copies/ml. Of the
313 ITT patients, 295 were treatment-naïve and 18 were
treatment-experienced with no darunavir RAMs. Overall,
86% of the ITT patients (268/313) completed the study
and 14% (45/313) discontinued, mainly for AEs (n =15)
and loss to follow-up (n =13) (Figure 1).
Overall, most patients were male (89%) and were White
(60%) or Black or of African Heritage (35%). The median
age was 35 years (range 18 to 72 years) (Table 1). Median
(range) baseline VL and CD4+ cell count were 4.8 (2.6 to
7.0) log10 HIV-1 RNA copies/ml and 361 (5 to 1473) cells/
mm3, respectively. Overall, 2% of patients were co-
infected with hepatitis B and 3% with hepatitis C virus.
Baseline characteristics of the treatment-naïve patient
population are shown in Table 1.
At baseline, one or more primary PI RAMs were
found in 10 patients (3%; nine treatment-naïve, and one
treatment-experienced), most commonly M46I/L (three
treatment-naïve and one treatment-experienced) and
Q58E (four treatment-naïve). No patients had darunavir
RAMs. Secondary PI RAMs were found in 96% of patients
(300/313; 283 and 17 patients), reflecting the strong poly-
morphic nature of these mutations. Non-nucleoside re-
verse transcriptase inhibitor (NNRTI) RAMs were found
in 28% of patients (87/313; 74 and 13 patients), most com-
monly K103N/S (13%; 41/313; 33 and eight patients). N[t]
RTI RAMs were found in 14% of patients (43/313; 36 and
seven patients), most commonly V118I (6%; 18/313; 18
and zero patients), T69D/N (3%; 8/313; eight and zero pa-
tients) and M184V/I (3%; 8/313; two and six patients).
Concomitant N[t]RTI use
The majority of patients (99%; 311/313 overall and 294/
295 treatment-naïve patients) received tenofovir-based
antiretroviral therapy during the study. The most fre-
quently used N[t]RTI combination was emtricitabine/
tenofovir (Table 1).
Adherence
During the course of the study, median adherence to daru-
navir and cobicistat in the overall population through
Week 48 as measured by pill count was 100%, and 299/313
Figure 1 Patient disposition through 48 weeks in the overall population.
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ence to darunavir and cobicistat in the treatment-naïve
population through Week 48 as measured by pill count
was also 100%, and 283/295 patients (96%) had a ≥90%
adherence rate.
Safety and tolerability
The overall median duration of exposure to study drugs
was 64.3 weeks (58.3 to 69.3 weeks); 268/313 (86%) pa-
tients received the study drugs for ≥48 weeks.
The most commonly reported treatment-emergent AEs
regardless of causality during the study were diarrhea,
nausea, upper respiratory tract infection and headache
(Table 2). The most common study drug-related AEs
through Week 48 were diarrhea (15%; 47/313 overall and
15%; 43/295 treatment-naïve patients), nausea (14%; 45/313
and 15%; 44/295, respectively), headache (4%; 13/313 and
4%; 12/295) and flatulence (4%; 13/313 and 4%; 13/295).
Most adverse events (AEs) were grade 1 or 2 in severity.
The incidence of any grade 3 or 4 treatment-emergent
AEs regardless of causality through Week 24 (primary
endpoint) was low (Table 2). Overall, 16 patients experi-
enced grade 3 (5%) and two patients experienced grade 4
(0.6%) AEs. Among the treatment-naïve patients, throughWeek 48, the most common grade 3 or 4 AEs regard-
less of causality (occurring in ≥2 patients) were hyper-
sensitivity (grade 3: two patients; grade 4: one patient),
maculo-papular rash (grade 3: two patients) and periph-
eral neuropathy (grade 3: two patients). Any study drug-
related grade 3 AE occurred in five patients (2%). These
grade 3 AEs were immune reconstitution syndrome (one
patient), hypersensitivity (two patients), maculo-papular
rash (one patient), and allergic dermatitis, maculo-papular
rash and vesicular rash (all occurring in the same patient),
and all led to study drug discontinuation. One patient had
grade 4 thrombocytopenic purpura, which was considered
serious and led to study drug discontinuation, but was not
considered related to study drug. Another patient had
grade 4 hypersensitivity, which was considered serious and
led to study drug interruption, but was not considered re-
lated to study drug, but related to concomitant lisinopril.
Three serious AEs, all occurring in treatment-naïve
patients, were felt to be related to study drug. One pa-
tient each reported immune reconstitution syndrome,
rash and maculo-papular rash. There were no deaths. The
most commonly reported AEs that led to discontinuation
through Week 48 were rash and maculo-papular rash,
nausea and hypersensitivity (Table 2). All these AEs were
Table 1 Patient baseline demographics and disease characteristics and background N[t]RTIs
All patients N = 313 Treatment-naïve patients N = 295
Male [n (%)] 279 (89) 266 (90)
Age, years [median (range)] 35 (18–72) 34 (18–72)
Race [n (%)]
White 187 (60) 176 (60)
Black or African Heritage 108 (35) 101 (34)
Asian 4 (1) 4 (1)
Other 14 (4) 14 (5)
Log10 VL (HIV-1 RNA copies/ml) [median (range)] 4.8 (2.6–7.0) 4.8 (2.6–7.0)
VL >100,000 HIV-1 RNA copies/ml [n (%)] 131 (42) 122 (41)
CD4+ cell count (cells/mm3) [median (range)] 361 (5–1473) 370 (6–1473)
≤200 cells/mm3 [n (%)] 59 (19) 47 (16)
Asymptomatic HIV infection [n (%)] 251 (80) 241 (82)
Co-infection with HBV [n (%)] 5 (2) 5 (2)
Co-infection with HCV [n (%)] 8 (3) 7 (2)
eGFRCG, ml/min [median (range)] 114 (67–321) 115 (67–321)
Background N[t]RTIs [n (%)]
Emtricitabine/tenofovir 301 (96) 291 (99)
Emtricitabine/tenofovir plus zidovudine 5 (2) 0
Abacavir plus tenofovir 3 (1) 2 (0.7)
Emtricitabine/tenofovir plus abacavir 2 (0.6) 1 (0.3)
Abacavir/lamivudine 1 (0.3) 1 (0.3)
Didanosine plus emtricitabine 1 (0.3) 0
N number of patients; n number of patients with observations; VL viral load; HBV hepatitis B virus; HCV hepatitis C virus; eGFRCG estimated glomerular filtration rate
calculated using the Cockcroft-Gault method; N[t]RTIs nucleoside/tide reverse transcriptase inhibitors.
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tinuation. One treatment-naïve patient discontinued be-
cause of renal tubular disorder, which was mild in severity,
not serious and resolved following change in therapy to
darunavir/ritonavir plus lamivudine and abacavir. Eight
bone fractures were reported through Week 48, each with
traumatic mechanisms and without features concerning
for fragility fracture.
There was an increase in serum creatinine level from
baseline occurring as early as Week 2 (median change =
0.10 mg/dl overall and in treatment-naïve patients),
which remained stable throughout the Week 48 treat-
ment period (median change =0.09 mg/dl and 0.08 mg/dl,
respectively) and is consistent with cobicistat inhibition of
creatinine secretion. There were no other clinically rele-
vant changes from baseline in median values for other
clinical laboratory parameters.
Virologic response
Overall, the virologic response rate (Food and Drug Ad-
ministration [FDA] snapshot analysis) was 82% (258/313)
(95% confidence interval [CI] 78%, 87%) at Week 24 and
was sustained and durable through Week 48 (81%; 95% CI76%, 85%; Table 3 and Figure 2). Virologic failure occurred
in 11% of patients at Week 48, and 9% had no virologic
data in the Week 48 window.
In treatment-naïve patients, the Week 48 virologic res-
ponse rate was 83% (244/295; 95% CI 78%, 87%). Twenty
four treatment-naïve patients (8%) were classed as viro-
logic failures, and 27 treatment-naïve patients (9%) had no
virologic data in the Week-48 window.
The Week 48 rates of virologic response were compar-
able in patients who had a baseline VL ≤100,000 HIV-1
RNA copies/ml or >100,000 HIV-1 RNA copies/ml,
both overall (81% vs. 80%, respectively) (Table 3) and
in treatment-naïve patients (84% vs. 81%).
Sensitivity analyses showed the Week 48 virologic re-
sponse rate was 81% (253/313) overall and 83% (245/
295) in treatment-naïve patients using the time-to-loss
of virologic response (TLOVR) analysis, and it was 83%
(260/313) and 85% (250/295), respectively, using the
missing = failure (M = F) method.
Immunologic response
There was an increase in CD4+ cell count from baseline
at all timepoints following initiation of study drugs. At
Table 2 Treatment-emergent AEs and grade 3–4 laboratory abnormalities
All patients Treatment-naïve patients
Incidence, [n (%)] Week 24 analysis Week 48 analysis Week 48 analysis
N = 313 N = 313 N = 295
Grade 3–4 AEs 18 (6) 24 (8) 21 (7)
Any AE 275 (88) 286 (91) 270 (92)
Any drug-related AE 123 (39) 128 (41) 122 (41)
Serious AEs 15 (5) 26 (8) 21 (7)
Deaths 0 0 0
AEs any grade, regardless of relationship to study treatment and occurring in ≥10% of patients
Diarrhea 78 (25) 86 (27) 80 (27)
Nausea 67 (21) 72 (23) 69 (23)
Upper respiratory tract infection 31 (10) 44 (14) 43 (15)
Headache 29 (9) 38 (12) 35 (12)
AEs leading to discontinuation*
Any, n 15 (5) 16 (5) 16 (5)
Maculo-papular rash 3 (1) 3 (1) 3 (1)
Rash 3 (1) 3 (1) 3 (1)
Nausea 2 (0.6) 2 (0.6) 2 (0.7)
Hypersensitivity 2 (0.6) 2 (0.6) 2 (0.7)
Idiopathic thrombocytopenic purpura 1 (0.3) 1 (0.3) 1 (0.3)
Dyspepsia 1 (0.3) 1 (0.3) 1 (0.3)
Vomiting 1 (0.3) 1 (0.3) 1 (0.3)
Mycobacterium avium complex infection 1 (0.3) 1 (0.3) 1 (0.3)
Headache 1 (0.3) 1 (0.3) 1 (0.3)
Dysgeusia 1 (0.3) 1 (0.3) 1 (0.3)
Renal tubular disorder – 1 (0.3) 1 (0.3)
Allergic dermatitis 1 (0.3) 1 (0.3) 1 (0.3)
Macular rash 1 (0.3) 1 (0.3) 1 (0.3)
Vesicular rash 1 (0.3) 1 (0.3) 1 (0.3)
Treatment-emergent grade 3–4 laboratory abnormalities occurring in ≥2% patients
n = 310 n = 310 n = 292
Increased creatine kinase 18 (6) 22 (7) 22 (8)
Increased alanine amino transferase 7 (2) 9 (3) 9 (3)
Increased aspartate amino transferase 6 (2) 8 (3) 7 (2)
Increased amylase 6 (2) 8 (3) 7 (2)
Increased lipase 5 (2) 7 (2) 7 (2)
N number of patients; n number of patients with observations; AE adverse event. Serious AEs included any AE that occurred at any dose that resulted in death, a
life-threatening situation, inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a patient who
received investigational medicinal product; *Patients may have discontinued due to more than 1 AE.
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dian (range) increases from baseline in CD4+ cell count
(missing = excluded) were 131 (−471 to 596) cells/mm3
and 167 (−193 to 1086) cells/mm3, respectively (Figure 2).
In treatment-naïve patients, the median (range) CD4+ cell
count increased by 169 (−193 to 1086) cells/mm3 from
baseline to Week 48.Development of resistance
Of the 15 patients with samples eligible for resistance
analysis (Table 4), three had suboptimal virologic re-
sponse, eight had virologic rebound, and four who dis-
continued with VL ≥400 HIV-1 RNA copies/ml were
analyzed at their last visit. Only one of these 15 patients
who was treatment experienced (prior antiretrovirals
Table 3 Virologic outcome at Week 24 and 48 according to the FDA Snapshot* analysis in the overall population
Week 24 Week 48
Outcomes, [n (%)] VL ≤100 K HIV-1 VL >100 K HIV-1 VL ≤100 K HIV-1 VL >100 K HIV-1
Total RNA copies/ml RNA copies/ml Total RNA copies/ml RNA copies/ml
n = 313 n = 182 n = 131 n = 313 n = 182 n = 131
Virologic response 258 (82) 157 (86) 101 (77) 253 (81) 148 (81) 105 (80)
Virologic failure 36 (12) 10 (5) 26 (20) 33 (11) 14 (8) 19 (15)
VL ≥50 HIV-1 RNA copies/ml 22 (7) 4 (2) 18 (14) 14 (4) 5 (3) 9 (7)
Discontinued drug due to lack of efficacy 0 0 0 0 0 0
Discontinued drug due to other reasons and
last available VL ≥50 HIV-1 RNA copies/ml
14 (4) 6 (3) 8 (6) 19 (6) 9 (5) 10 (8)
No virologic data in the analysis window 19 (6) 15 (8) 4 (3) 27 (9) 20 (11) 7 (5)
Discontinued drug to AE 14 (4) 12 (7) 2 (2) 15 (5) 13 (7) 2 (2)
Discontinued drug for other reason and last
VL <50 HIV-1 RNA copies/ml
3 (1) 2 (1) 1 (1) 10 (3) 5 (3) 5 (4)
Missing data during window but on drug 2 (1) 1 (1) 1 (1) 2 (1) 2 (1) 0
*Proportion of patients with VL <50 HIV-1 RNA copies/ml during Week 24 or Week 48 window; N number of patients; n number of patients with observations;
AE adverse event, VL viral load.
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fumarate, zidovudine, lamivudine, stavudine) developed
a resistance mutation to darunavir (at position I84 as a
mixture with wild-type, I84I/V) (Table 4); this was not
associated with phenotypic resistance to darunavir or
other PIs. Two patients (one treatment-experienced and
one treatment-naïve) developed the M184V N[t]RTI
RAM in reverse transcriptase while receiving emtricita-
bine (Table 4) that was associated with phenotypic re-
sistance to emtricitabine and lamivudine. One patient
(patient 14 in Table 4) showed the transient development
of the N[t]RTI RAM L74I/L and the NNRTI RAM
P225H/P at the Week 16 visit, which were not detected at
the subsequent Week 48 visit analysis as shown in Table 4.
These mutations were not associated with resistance to
the agents in the patient’s regimen (emtricitabine/tenofo-
vir/zidovudine), and may reflect previous drug history.
New primary RAMs were not detected in the 11
remaining patients.
Pharmacokinetics
Sixty patients were enrolled in the pharmacokinetic sub-
study. Pharmacokinetic parameters were comparable to
historic data. For darunavir, mean (standard deviation
[SD]) maximum plasma concentration (Cmax) was 7663
(1920) ng/ml, minimum plasma concentration (Cmin)
was 1310 (969) ng/ml and area under the concentra-
tion–time curve during a 24-hour interval (AUC24h) was
81,646 (26,322) ng•h/ml (Table 5). Pharmacokinetics of
cobicistat, tenofovir and emtricitabine are shown in
Table 5.
In the Bayesian feedback analysis for darunavir population
pharmacokinetic parameters through Week 48 (n = 298),
the overall mean (SD) population pharmacokinetic-derived darunavir AUC24h and trough plasma concentra-
tion (C0h; n = 298) at Week 48 were 102,000 (33,100)
ng•h/ml and 2150 (1320) ng/ml, respectively. Data were
available for 281 treatment-naïve patients. The mean (SD)
darunavir AUC24h was 100,620 (32,366) ng•h/ml and
C0h was 2105 (1289) ng/ml. In 17 treatment-experienced
patients, the mean (SD) darunavir AUC24h was 119,747
(39,961) ng•h/ml and C0h was 2917 (1658) ng/ml.
These values are comparable to those previously reported
for darunavir/ritonavir 800/100 mg once daily (mean [SD]
AUC24h and C0h were 93,026 [27,050] ng•h/ml and 2282
[1168] ng/ml, respectively, in antiretroviral-naïve pa-
tients [33] and 93,334 [28,626] ng•h/ml and 2160
[1201] ng/ml, respectively, in treatment-experienced
patients with no darunavir RAMs [34]). There were no
clinically relevant relationships between darunavir ex-
posure and virologic response, AEs or laboratory
parameters.
Discussion
This Phase IIIb study was conducted to evaluate the safety,
efficacy and pharmacokinetics of darunavir/cobicistat 800/
100 mg once daily in HIV-1-infected adults with no daru-
navir RAMs who also received two fully active N[t]RTIs.
We showed that darunavir/cobicistat 800/150 mg once
daily was well tolerated, and the pharmacokinetics, viro-
logic and immunologic responses were consistent with
previously published data for darunavir/ritonavir 800/
100 mg once daily.
Through Week 24, the onset of any grade 3 or 4 AEs
regardless of causality was low (6% in the overall popula-
tion). Five out of 313 patients (2%), all of whom were
treatment-naïve, experienced any study drug-related grade
3 AE through Weeks 24 and 48. No patients experienced
Figure 2 Efficacy through 48 weeks in the overall population. (a) Proportions of viral load responders (<50 copies/ml: FDA snapshot analysis)
through 48 weeks (N =313); (b) Median (range) change in CD4+ cell count (cells/mm3) from baseline through 48 weeks (missing = excluded).
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AEs of all grades during the study, diarrhea, nausea, upper
respiratory tract infection and headache, have all been re-
ported previously for darunavir and cobicistat [5-8,15,16].
Renal laboratory assessments showed small changes con-
sistent with the inhibitory effects of cobicistat on renal
tubular creatinine secretion rather than a true reduction
in GFR [15,16,29].
Darunavir and cobicistat administered once daily with
two fully active N[t]RTIs, gave a virologic response rate
at Week 48 of 81% overall and 83% in treatment-naïve
patients (FDA Snapshot analysis) and improved CD4+
cell counts over 48 weeks. The Week 48 FDA Snapshot re-
sponse rate was consistent with responses using secondaryanalyses, including the TLOVR analysis (81% response
overall and 83% in treatment-naïve patients), and with the
Week 48 virologic response rate in treatment-naïve pa-
tients in ARTEMIS (84%; TLOVR, ITT analysis) [5]. As in
ARTEMIS, virologic responses were similar irrespective of
baseline VL.
In this study, only 15/313 patients met the criteria for
resistance analysis. One of these 15 patients who was
treatment experienced, developed a darunavir RAM at
position I84 as a mixture with wild-type (I84I/V), which
was not associated with phenotypic resistance to darunavir
or other PIs. Two patients (one treatment experienced
and one treatment naïve) developed the M184V RAM
while receiving emtricitabine as part of their backbone









1 Abacavir plus tenofovir Naïve 24 None None
2 Emtricitabine/tenofovir Naïve 12 None None
3 Emtricitabine/tenofovir Naïve 48 I93I/L I142L/P
4 Emtricitabine/tenofovir Experienced 24 None K22K/R
5 Emtricitabine/tenofovir Naïve 36 R57R/K M184V
6 Emtricitabine/tenofovir Naïve 16 V32V/A, P39P/S K122K/E, D123D/G/N/S, D177D/G, I178M
7 Emtricitabine/tenofovir Naïve 48 None D123D/E
8 Emtricitabine/tenofovir Experienced 48 None K122K/E, A272A/P
9 Emtricitabine/tenofovir Experienced 12 I84I/V E138T, T165A/E, R211R/K
10 Emtricitabine/tenofovir Naïve 8 G86G/E D123N
11 Emtricitabine/tenofovir plus zidovudine Experienced 48 None I195I/L
12 Abacavir plus tenofovir Experienced 36 R41R/K None
13 Emtricitabine/tenofovir Naïve 48 V77V/I E6E/K, E224E/Q, V245Q, T286T/A, V292V/I
14 Emtricitabine/tenofovir plus zidovudine Experienced 48 None E6E/D, V60I
15 Emtricitabine/tenofovir Experienced 36 None M184V
*Compared to screening genotype – emerging primary resistance-associated mutations (RAMs) are shown in bold; N[t]RTI nucleoside/tide reverse
transcriptase inhibitor.
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to both lamivudine and emtricitabine. In the remaining
12 patients who were analyzed for resistance, no new
primary RAMs were detected. The low rates of resistance
development in this study confirms the high genetic
barrier of darunavir whether boosted with cobicistat or
ritonavir.
Steady-state darunavir pharmacokinetic parameters in
the pharmacokinetic substudy were consistent with those
observed in previous Phase I studies in healthy volunteers
[30-32]. When data from all evaluable patients were in-
cluded into a more robust dataset, the population-based
darunavir pharmacokinetic parameters were consistent
with previous data with darunavir/ritonavir 800/100 mg
once daily in HIV-1-infected, treatment-naïve patients
in ARTEMIS, and treatment-experienced patients with
no darunavir RAMs in ODIN [33,34]. In the popula-
tion pharmacokinetic model, the mean darunavir C0h
of 2150 ng/ml was >37-fold above the protein-bindingTable 5 Summary of pharmacokinetic parameters in the subs
Pharmacokinetic parameters Darunavir C
n = 60
AUCtau, ng•h/ml [mean (SD)] 81,646 (26,322)* 75
Cmax, ng/ml [mean (SD)] 7663 (1920)
Ctau, ng/ml [mean (SD)] 1311 (969)*
C0h, ng/ml [mean (SD)] 1560 (1328)
Tmax, h [median (Q1, Q3)] 3.50 (2.49, 4.29) 3.5
t1/2, h [median (Q1, Q3)] 7.24 (5.35, 11.54)
‡ 3.25
*n = 59; †n = 58; ‡n = 55; §n = 56.adjusted 50% effective concentration for wild-type virus
(55 ng/ml) [33,35], indicating adequate pharmacokinetic
boosting of darunavir by cobicistat.
The mean steady-state cobicistat pharmacokinetic pa-
rameters (AUCtau 7596 ng•h/ml and Cmax 991 ng/ml)
were consistent with levels associated with pharmacoki-
netic enhancement and in the range of historical data in
HIV-1-infected patients (AUCtau 8300 ng•h/ml and Cmax
1100 ng/ml). Steady-state emtricitabine and tenofovir
pharmacokinetic parameters were also in the range of
historical data [36-38].
No clinically relevant relationship was observed bet-
ween darunavir AUC24h or C0h and virologic response or
safety at Week 24 or 48 when given with cobicistat. This
is consistent with previous data with darunavir/ritonavir
in ARTEMIS [33] and ODIN [34].
The fixed-dose combination of darunavir and cobicistat
reduces pill burden compared with separately adminis-
tered darunavir and ritonavir. Accordingly, the fixed-dosetudy
obicistat Emtricitabine Tenofovir
96 (3657)* 11,793 (3490)† 3613 (1203)†
991 (331) 1862 (491)* 382 (118)*
33 (95)* 113 (101)† 78 (33)†
76 (186) 147 (171)* 84 (45)*
0 (2.01, 4.50) 2.02 (2.00, 3.50)* 2.00 (1.00, 3.05)*
(2.91, 3.81)* 7.14 (6.44, 7.86)§ 13.34 (11.68, 15.35)§
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plicity, and therefore patient adherence to medication
[18-22]. Cobicistat does not induce CYP isozymes and
is a more selective inhibitor of CYP3A than ritonavir
[13,14], so there is less potential for drug–drug interac-
tions to occur than with ritonavir.
The study was limited in that it was an open-label,
single-arm study. As such, it did not directly compare
darunavir/cobicistat against darunavir/ritonavir. Never-
theless, previous studies have shown the fixed-dose com-
bination of darunavir/cobicistat 800/150 mg once daily
has darunavir pharmacokinetic parameters comparable
to those of darunavir/ritonavir 800/100 mg once daily
[30-32]. These comparable pharmacokinetic parameters
are expected to translate into similar efficacy, as has been
shown in an indirect comparison of darunavir/cobicistat
data from the current study and combined darunavir/rito-
navir data from ARTEMIS (treatment-naïve patients) and
ODIN (treatment-experienced patients with no darunavir
RAMs) [39].
Secondly, the study included a heterogeneous group of
patients with no darunavir RAMs, consistent with the
current prescribing information of darunavir 800 mg
once daily; however, the majority (94%) was treatment
naïve. Separate reporting of the treatment-experienced
cohort would not be meaningful given the small number
of these patients (n =18).
In conclusion, darunavir and cobicistat was generally
well tolerated, and with a safety profile that was consist-
ent with the one of each agent separately. The combin-
ation achieved high rates of virologic suppression over
48 weeks, with only one patient developing a darunavir
RAM but without phenotypic resistance to darunavir or
other PIs. The steady-state pharmacokinetic parameters
for darunavir, cobicistat, emtricitabine and tenofovir fol-
lowing administration of darunavir and cobicistat once
daily and two fully active N[t]RTIs were consistent with
previously published data. These data support the use of
darunavir/cobicistat in combination with N[t]RTIs for




Adult HIV-1-infected, treatment-naïve or treatment-
experienced (on a stable antiretroviral regimen for ≥12
weeks prior to screening) patients with no darunavir
RAMs were recruited. Patients were required to have
plasma VL ≥1000 HIV-1 RNA copies/ml (Amplicor HIV-1
Monitor Test, version 1.5, Roche Diagnostics, Basel,
Switzerland) at screening, eGFRCG ≥80 ml/min, geno-
typic sensitivity to the two investigator-selected N[t]RTIs
(GenoSure MG™ assay, Monogram Biosciences, South San
Francisco, CA, USA), and none of the following darunavirRAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P,
L76V, I84V or L89V [40]. Exclusion criteria included pre-
vious or current use of darunavir, a newly diagnosed
AIDS-defining condition, proven or suspected acute hepa-
titis or treatment for hepatitis C, and females who were
pregnant or breastfeeding.
Prior to study start, the trial protocol was reviewed
and approved by an independent ethics committee or an
institutional review board at each study site. The trial
was conducted according to the International Confe-
rence on Harmonization guideline for Good Clinical
Practice and principles of Good Clinical Practice and
Declaration of Helsinki. All patients provided written
informed consent.
Study design and treatment
This was an open-label, single-arm, multicenter, 48-week,
Phase IIIb trial (NCT01440569) conducted at 56 sites in
the USA to evaluate the safety, efficacy and pharmacokin-
etics of cobicistat-boosted darunavir (as single agents) plus
two fully active N[t]RTIs in HIV-1-infected adults with no
darunavir RAMs. The trial consisted of a ≤35-day screen-
ing period, a 48-week treatment period and a follow-up
visit 30 days after last drug intake or study discontinu-
ation, unless patients participated in an open-label rollover
study and continued receiving treatment.
Patients received darunavir 800 mg (2 x 400-mg tablets)
once daily plus cobicistat (150-mg tablet) once daily, both
taken with food and two N[t]RTIs, administered orally.
For any patients with the M184V/I RAM present at scree-
ning, emtricitabine or lamivudine could be included as a
third (not fully active) N[t]RTI for the purpose of main-
taining M184V/I. Prior to Week 48, changes to the study
regimen were only permitted for management of subopti-
mal antiviral efficacy.
An optional substudy assessed darunavir, cobicistat,
emtricitabine and tenofovir pharmacokinetics. The phar-
macokinetic substudy included intensive pharmacoki-
netic sampling over 24 hours and was performed in a
subset of patients (target n =48 evaluable) at selected
study sites.
Study endpoints and assessments
The primary endpoint of the study was any treatment-
emergent grade 3 (severe) or grade 4 (life threatening)
AEs occurring through Week 24. Secondary outcome
measures included any treatment-emergent AE through
Weeks 24 and 48, including those leading to discontinu-
ation of study drug, and antiviral efficacy at Weeks 24
and 48.
Assessments for AEs (graded according to the Gilead
Sciences, Inc. Grading Scale for Severity of Adverse Events
and Laboratory Abnormalities) and laboratory parameters
(e.g. serum chemistry, hematology, urinalysis, eGFRCG,
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baseline and at Weeks 2, 4, 8, 12, 16, 24, 36 and 48. A
12-lead electrocardiogram was performed at screening
only. Safety analyses also included data collected on or
after study drug administration through 30 days after
the last dose of study drugs for patients who disconti-
nued. AEs were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) Version 15.1.
Treatment adherence was assessed by median pill
count, which was calculated as the number of pills taken
divided by the number of pills prescribed. The propor-
tion of patients in specified adherence categories (<90%
or ≥90%) was also calculated.
HIV-1 protease and reverse transcriptase genotype/
phenotype testing (PhenoSense GT™ assay, Monogram
Biosciences, South San Francisco, CA, USA) was per-
formed on samples from patients with VL ≥400 HIV-1
RNA copies/ml who had a suboptimal virologic response
(VL <1 log10 HIV-1 RNA copies/ml reduction from base-
line and ≥50 HIV-1 RNA copies/ml at the Week 8 visit,
confirmed at the Week 12 visit) or who had a con-
firmed virologic rebound (VL <50 HIV-1 RNA copies/
ml followed by a confirmed VL ≥400 HIV-1 RNA copies/
ml or a >1 log10 HIV-1 RNA copies/ml increase in VL
from the nadir) or discontinued (after Week 8) while
receiving study drugs. Baseline protease/reverse tran-
scriptase phenotyping was performed retrospectively on
patients with confirmed virologic failure only if they
showed evidence of reduced susceptibility to darunavir
or N[t]RTIs in the background regimen.Pharmacokinetic measurements
For the whole study population, sparse blood samples for
analysis of study drug plasma concentrations were col-
lected over 24 hours at Weeks 2, 4, 8, 12, 16, 24, 36 and
48. For the pharmacokinetic substudy, plasma samples
were collected predose, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12 and
24 hours post-dose at a visit between Weeks 2 and 8.
Darunavir [41], cobicistat [14], emtricitabine [42] and
tenofovir [42] plasma concentrations were assayed using
validated liquid chromatography–mass spectrometry/mass
spectrometry, with a lower limit of quantification of
5 ng/ml for darunavir, cobicistat and emtricitabine
and 10 ng/ml for tenofovir.
For the pharmacokinetic substudy, steady-state pharma-
cokinetic parameters (Cmax, Cmin and AUC24h) were ob-
tained using non-compartmental analysis (WinNonlin®
software version 6.2, Pharsight Corporation, Mountain
View, CA, USA). The intensive pharmacokinetic substudy
data was used to revise an existing 2-compartment po-
pulation pharmacokinetic model with first-order absorp-
tion [43]. The population pharmacokinetic model was
then used to derive individual empirical Bayes estimates ofdarunavir exposure (AUC24h and C0h) at all visits using
NONMEM.
Pharmacokinetic/pharmacodynamic relationships were
assessed using darunavir exposure and virologic response
at Week 48. The absence or presence of select AEs (rash,
diarrhea, nausea or vomiting) and worst change in labo-
ratory parameters (alkaline phosphatase, alanine transami-
nase, aspartate aminotransferase, amylase, lipase, glucose,
total cholesterol, low-density lipoprotein-cholesterol, high-
density lipoprotein-cholesterol or triglyceride) by daruna-
vir AUC24h was evaluated.Data analyses
Power calculations prior to study design calculated a
sample size of 300 patients would provide a 95% chance
of observing ≥1 grade 3 or 4 AE if the true incident
rate of the AE was 1%. This sample size would also
produce a two-sided 95% CI with a half-width of 4.7%
based on an assumed virologic response rate for PIs (pro-
portion of patients with VL <50 HIV-1 RNA copies/ml)
of 80%.
The ITT population included all patients who were
enrolled in the study and received at least one dose of
darunavir and cobicistat.
Given the association between tenofovir and renal and
bone events, and that the majority of the patients were
receiving this therapy, a prespecified analysis of selected
renal events (Fanconi syndrome, renal failure and renal
tubular disorder) and bone fractures was conducted.
The primary efficacy analysis was the virologic response
rate at Week 24 or 48 by the Snapshot algorithm [44].
Virologic failure was defined as VL ≥50 HIV-1 RNA
copies/ml, discontinuation of study drug prior to Week
24 or 48 due to lack of efficacy, or discontinuation due
to other reasons with last available VL >50 HIV-1 RNA
copies/ml. Patients with no virologic data in the Week
24 or 48 window were classified as treatment failures.
Secondary efficacy analyses included virologic response
rates according to the TLOVR imputation algorithm
and the M = F analysis.
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